Join

Compare · DMPI vs TRIL

DMPI vs TRIL

Side-by-side comparison of DelMar Pharmaceuticals, Inc. (DMPI) and Trillium Therapeutics Inc. (TRIL): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both DMPI and TRIL operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
  • TRIL carries a market cap of $1.94B.
  • TRIL has more recent analyst coverage (5 ratings vs 0 for DMPI).
MetricDMPITRIL
Company
DelMar Pharmaceuticals, Inc.
Trillium Therapeutics Inc.
Price
-
$19.30-3.45%
Market cap
-
$1.94B
1M return
-
-3.79%
1Y return
-
-5.02%
Sector
Health Care
Health Care
Industry
Major Pharmaceuticals
Major Pharmaceuticals
Exchange
NASDAQ
NASDAQ
IPO
n/a
n/a
News (4w)
0
0
Recent ratings
0
5
TRIL

Trillium Therapeutics Inc.

Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was incorporated in 2004 is based in Mississauga, Canada.

Latest DMPI

No recent items for DelMar Pharmaceuticals, Inc..

Latest TRIL